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Inflammatory biomarkers, including cytokines, are associated with COPD, but the association of particular circulating cytokines
with systemic pathology remains equivocal. To investigate this, we developed a protein microarray system to detect multiple
cytokines in small volumes of serum. Fourteen cytokines were measured in serum from never-smokers, ex-smokers, current
smokers, and COPD patients (GOLD stages 1–3). Certain individual circulating cytokines (particularly TNF𝛼 and IL-1𝛽) were
significantly elevated in concentration in the serum of particular COPD patients (and some current/ex-smokers without COPD)
and may serve as markers of particularly significant systemic inflammation. However, numerous circulating cytokines were raised
such that their combined, but not individual, elevationwas significantly associated with severity of disease, and thesemay be further
indicators of, and contributors to, the systemic inflammatory manifestations of COPD. The coelevation of numerous circulating
cytokines in COPD is consistent with the insidious development, chronic nature, and systemic comorbidities of the disease.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality worldwide. It is induced
mainly by tobacco smoking, which leads to chronic, irre-
versible lung inflammation; both cellular and humoral
immunological processes are involved in the pathology [1–6].
A significant proportion of patients also have other disease
manifestations (e.g., cardiovascular disease, metabolic dis-
ease, bone disease, and cachexia), which are associated with
systemic inflammation [1, 7–10]. Inflammatory biomarkers,
including cytokines, are associated with both the lung disease
and the systemic pathology [1, 11–22]. These circulating
cytokines could be “spill over” from lung inflammation or
induced separately from pathological processes in the lung;
evidence for the latter is differences in cytokine profiles seen
in the lung and circulation, and only a proportion of COPD
patients show a significant rise in individual circulating
cytokines [1].
Cytokines are not disease-specific biomarkers, as they
may be raised for many different reasons (e.g., infection,
autoimmunity, and intrinsic inflammation), which may be
subclinical; therefore, some never-smokers with no overt
clinical disease may have raised cytokines, as well as smokers
and COPD patients. This is one of the reasons why it is
difficult to identify particular individual circulating cytokines
as disease-specific markers for COPD.
Some previous studies have investigated a broad range of
systemic cytokines in COPD [11–14], but others have exam-
ined only a few. In general, relatively large cohorts of patients
and controls have been required to demonstrate statistically
significant elevation of individual cytokines in COPD, and
different studies have concluded that different cytokines are
raised [15–20]. This suggests that systemic inflammation in
COPD occurs in only a proportion of patients with lung dis-
ease (as evidenced by others, e.g., [15]) and/or a subtle, broad
elevation of numerous cytokines is associated with the sys-
temic inflammation. To investigate this further, we developed
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Table 1: Demographic data of subjects.
Group Never-smokers(NS)
Ex-smokers
(ExS)
Current smokers
(CS)
COPD GOLD
stage 1 (S1)
COPD GOLD
stage 2 (S2)
COPD GOLD
stage 3 (S3)
Number 11 25 9 7 37 13
Age (yrs)
Median (range)∗ 56 (41–67) 71 (42–80) 69 (42–76) 65 (61–82) 68 (46–82) 67 (47–84)
F/M 6/5 12/13 3/6 2/5 18/19 5/8
FEV1-%
Median (range)§ 97 (87–134) 98 (74–124) 96 (84–115) 87 (80–103) 62 (51–77) 42 (30–49)
Ex-smokers 0 25 0 4 30 8
Current smokers 0 0 9 3 7 5
∗The age of the NS group was significantly different from S2; there were no other significant age differences between groups (by Kruskal-Wallis test with Dunn’s
post hoc test for multiple comparisons).
§The NS, ExS, and CS groups were all significantly different from both S2 and S3 for FEV1-% of predicted, and S1 was significantly different from S3; there were
no other significant differences between groups (by Kruskal-Wallis test with Dunn’s post hoc test for multiple comparisons).
an in-house protein microarray system to detect multiple
cytokines in small volumes of serum. The system was rigor-
ously validated for accuracy and reproducibility and reported
previously in this journal [23]. Patients with mild, moder-
ate, or severe COPD [GOLD (global initiative for chronic
obstructive lung disease) stages 1–3] were investigated in
comparison with never-smokers (NS) and current smokers
without COPD (CS).
2. Materials and Methods
2.1. Subjects. Serum was obtained from 57 patients with
confirmed COPD, 25 ex-smokers without COPD (ExS), 9
current smokers without COPD (CS), and 11 never-smoker
(NS) healthy controls. Subjects were recruited from volunteer
databases and respiratory out-patient clinics and by adver-
tisement. All subjects were over 40 years of age, of European
descent, had a significant smoking history of greater than 10
pack years, and were studied at clinical stability (no change
in regular therapy, no requirement for antibiotics and/or oral
corticosteroids in the preceding 4 weeks, and no change in
symptoms beyond day-to-day variation). All subjects gave
written informed consent and the study was approved by
the National Research Ethics Committee [Leicestershire,
Northamptonshire, Rutland (LNR), REC 10/H0406/65]. No
subject recruited had active or suspected malignancy, termi-
nal disease, or known alpha-1-antitrypsin deficiency. Samples
were collected and stored at −70∘C until used. The demo-
graphics of the groups are shown in Table 1 and described in
Section 3.
2.2. Cytokine Microarray. Serum cytokine concentrations
were determined by protein microarray, as described in
detail previously in this journal [23]. Briefly, capture anti-
bodies from DuoSet kits (R&D Systems, MN, USA) were
printed onto poly-L-lysine slides. The slides were blocked
with either I-Block or 3% BSA block buffer. Standards were
made for all 14 cytokines (see Figure 1) according to the
manufacturer’s instructions and 7 twofold dilutions were
applied to the microarrays. Additionally, the NS, CS, and
COPD sera were added to microarray slides. The slides
were washed and 50 𝜇L of appropriately diluted DuoSet
biotinylated detection antibody (R&D Systems, MN, USA)
were added, followed by streptavidin-HRP (Bio-Rad, USA).
The slides were washed and 50𝜇L of Bio-Rad Amplification
Reagent (Opti-4CN amplification kit) was added for 10
minutes in the dark. The slides were washed extensively with
20% DMSO-PBST and with wash buffer, followed by the
addition of streptavidin-conjugated cy5 (E-Biosciences, UK).
The slides were scanned with a 4200AL microarray scanner
at 635 nm (Axon GenePix). Fluorescence was quantified
using theGenePix Pro Software (AxonGenePix).Themedian
fluorescence of each spot was measured (minus background)
and the corrected fluorescence was used to calculate the
average fluorescence signal across the standard detectable
ranges.
2.3. Statistical Analyses. The data were not normally dis-
tributed and therefore multiple comparisons between groups
weremade using the Kruskal-Wallis test for nonpaired data (5
comparisons) and the Friedman test for paired data (13 or 14
comparisons); in both cases Dunn’s post hoc test for multiple
comparisons was applied. Statistical analyses were performed
using GraphPad Prism 6 (La Jolla, California).
3. Results
3.1. Demographics of Study Groups. The demographics of the
subjects who donated serum for this study are shown in
Table 1. There were no significant age differences between
groups except for the never-smokers (NS) compared to the
COPDGOLDstage 2 (S2) patients, with theNS subjects being
slightly younger. Furthermore, serum levels ofmost cytokines
do not differ significantly between younger and older adults
[24]. Although the gender ratio varied, there are no signifi-
cant differences in peripheral blood cytokine concentrations
between females and males [25]. Patients with moderate or
severe COPD (GOLD stages 2-3) had significantly lower
FEV1-% than never-smokers or current/ex-smokers without
COPD.
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Figure 1: Continued.
4 Mediators of Inflammation
NS
ExS
CS
S1
S2
S3
0 600
Concentration (pg/mL)
100 200 300
(i) Eotaxin-1
NS
ExS
CS
S1
S2
S3
0 600 800 1600
Concentration (pg/mL)
200 400
(j) Eotaxin-2
0 20 40 300 600
Concentration (pg/mL)
NS
ExS
CS
S1
S2
S3
(k) IL-6
0 10 20 30 40 400 800
Concentration (pg/mL)
NS
ExS
CS
S1
S2
S3
(l) TNF𝛼
400 80020151050
Concentration (pg/mL)
NS
ExS
CS
S1
S2
S3
(m) IL-1𝛽
450300
NS
ExS
CS
S1
S2
S3
0 50 100 150
Concentration (pg/mL)
(n) VEGF
Figure 1: Concentrations of 14 cytokines in serum samples from control subjects and patients with COPD. The number of subjects in each
group was never-smokers (NS), 11; ex-smokers (ExS), 25; current smokers (CS), 9; COPD GOLD stage 1 (S1), 7; COPD S2, 37; COPD S3, 13.
Cytokines were measured by protein microarray (see text and [23] for details). Experiments were performed three times, with two replicates
in each experiment, and the data averaged across the three experiments. The data are presented as scatter plots, with each point representing
an individual subject’s serum sample, and the solid, short vertical lines show the median values for each cytokine in each group. The dotted
vertical lines represent the median values of the NS group.The dashed vertical lines represent the 95th percentile of the NS group: individual
cytokine concentrations higher than this are shown by black symbols and those below by grey symbols.
3.2. Effects of Smoking Status on Cytokine Levels. Fourteen
cytokines were measured in serum from never-smokers (NS,
11 subjects), ex-smokers without COPD (ExS, 25 subjects),
current smokers without COPD (CS, 9 subjects), and COPD
patients at GOLD stages 1–3 (S1, 7 subjects; S2, 37 subjects; S3,
13 subjects) by proteinmicroarray (Figure 1). [OneNS subject
and one CS subject were excluded from the above groups
because they had extremely elevated levels of numerous
cytokines compared to all other members of the group
(i.e., concentrations more than ×3 higher than any other
subjects in the groups). It was therefore judged that their
exceptionally high cytokine levels may have been indicative
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Figure 2: Median concentrations of 14 cytokines in serum samples
from the following groups of subjects: NS (𝑛 = 11), ExS (𝑛 = 25), CS
(𝑛 = 9), COPD ex-smokers (COPD-Ex, 𝑛 = 42), and COPD current
smokers (COPD-C, 𝑛 = 15).The symbol representing each cytokine
is shown in the figure.The solid, short horizontal lines represent the
median concentrations of the 14 cytokines in each group.Thedashed
horizontal line represents themedian value of the NS group. COPD-
Ex and COPD-C were significantly different from NS (∗), ExS (§),
and CS (†). There were no significant differences between NS, ExS,
and CS or between COPD-Ex and COPD-C. ∗ refers to significant
differences between the NS group and the COPD-Ex or COPD-C
groups. § refers to significant differences between the ExS group and
the COPD-Ex or COPD-C groups. † refers to significant differences
between the CS group and the COPD-Ex or COPD-C groups. The
number of symbols refer to the level of statistical significance, so
one symbol (∗, §, †) indicates 𝑝 = 0.03; two symbols (∗∗, §§,
††) indicate 𝑝 = 0.002; three symbols (∗ ∗ ∗, §§§, †††) indicate
𝑝 = 0.0002; four symbols (∗ ∗ ∗∗, §§§§, ††††) indicate 𝑝 < 0.0001;
these values were determined by Friedman test followed by Dunn’s
multiple comparisons test. The same applies to Figures 3 and 4.
of other undiagnosed pathological processes, so they could
not be considered representative of the NS and CS groups.]
The majority of the COPD patients at all GOLD stages were
ex-smokers (COPD-Ex) and aminoritywere current smokers
(COPD-C). However, as shown in Figure 2, there were no
significant differences in themedian levels of the 14 cytokines
between the COPD-Ex and COPD-C groups, although both
of these groups had significantly higher levels of cytokines
overall compared to the NS (∗), ExS (§), and CS (†) groups
(Friedman test with Dunn’s post hoc test) (Figure 2). This
indicates that the elevation of serum cytokine concentrations
in the patients was principally a consequence of COPD
rather than their smoking status. Further comparisons were
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Figure 3: Median concentrations of 14 cytokines in serum samples
from the following groups of subjects: NS (𝑛 = 11), CS (𝑛 = 9),
COPD S1 (𝑛 = 7), COPD S2 (𝑛 = 37), and COPD S3 (𝑛 = 13). Other
details are as described in the legend to Figure 2. Compared to the
NS group, cytokines concentrations were significantly higher in the
S2 (∗) and S3 (∗ ∗ ∗) groups; similarly, compared to the CS group,
cytokines concentrations were significantly higher in the S2 (††) and
S3 (††††) groups.
therefore made between the NS, CS, and S1–3 groups in order
to identify the effects of smoking per se (in the CS subjects),
as well as the effects of the severity of COPD (in the S1–S3
subjects), on serum levels of the 14 cytokines studied.
3.3. Significant Elevation of Particular Serum Cytokines in
Individual Subjects. Figure 1 shows that numerous cytokines
were elevated in CS and, increasingly so, in S1 to S3; however,
none of these changes were statistically significant for partic-
ular cytokines in a group of subjects as a whole compared to
the NS group (Kruskal-Wallis test with Dunn’s post hoc test).
This could be partly because the levels of most cytokines vary
greatly, even in NS subjects, as is apparent in Figure 1. How-
ever, it could also be because only a proportion of patients
have a statistically significant rise of particular cytokines,
as has been reported by others [15], and suspected to
correspond with those patients with systemic inflammatory
disease. Therefore, as in previous studies, we defined indi-
vidual patients as showing significant elevation of particular
cytokines if their serum concentration exceeded the 95th per-
centile of theNS controls [15].This is shown for each cytokine
in Figure 1, where the dashed lines represent 95th percentile of
the serum cytokine concentrations in the NS group; subjects
with cytokine concentrations higher than this are shown
by black symbols, and those with lower concentrations are
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Figure 4: (a) Ratios of the median concentrations of each serum cytokine in the CS, S1, S2 and S3 groups expressed as percentages of these
median concentrations in the NS control group. The symbol representing each cytokine is as shown in (b)–(d). The solid, short horizontal
lines represent the median ratios to NS of the 13 cytokines in each group. The dashed horizontal line, which represents the median ratio to
NS of the CS group. Compared to the CS group, cytokine ratios to NS were significantly higher in the S2 (†) and S3 (†††) groups. (b)–(d)
Representations of the data in (a) presented to facilitate analysis of the relative difference in expression of each serum cytokine between the
CS, S1, S2 and S3 groups, divided into “Th1/Th2/Treg” cytokines (b), “chemokines” (c) and “inflammatory cytokines and growth factor” (d).
The dashed horizontal lines represent the standardised cytokine concentrations in the NS group (i.e., 100%).
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shown by grey symbols. Overall, at least one cytokine was
significantly elevated (i.e., >95th percentile of NS) in 22% CS,
43% S1, 43% S2, and 54% S3 subjects, 28 out of 66 subjects in
total, that is, 42% positive. Fifteen of the 28 positives had 2
or more cytokines raised, and several had multiple cytokines
raised, particularly in S2 subjects (the highest being 11/14
cytokines raised in one subject).The cytokines that weremost
frequently significantly elevated were TNF𝛼 (Figure 1(l)) and
IL-1𝛽 (Figure 1(m)); together, these detected 23/28 positives;
this is partly because the variations in levels of TNF𝛼 and IL-
1𝛽 in NS subjects were relatively small, thereby generating
low cut-off values for the 95th percentile (Figures 1(l) and
1(m), resp.). Out of the other five positives, two had elevated
IL-8 (Figure 1(f)), two VEGF (Figure 1(n)), and one TGF𝛽
(Figure 1(d)). Several subjects also had elevated levels of IL-
4 (Figure 1(b)), but all of these also had elevated TNF𝛼 and
IL-1𝛽.
3.4. Significant Summative Elevation of Multiple Serum
Cytokines in Subject Groups. The solid bars on the graphs in
Figure 1 represent the median serum concentrations of the
cytokines in each group of subjects. Figure 3 shows a plot of
these median cytokine concentrations for all 14 cytokines in
the NS, CS, and S1–3 groups. It can be seen that, compared
to NS, there is a gradual, general increase of serum cytokine
concentrations with increasing disease severity (CS < S1 < S2
< S3). Furthermore, the collective serum cytokine concen-
trations in S2 and S3 were significantly raised compared to
both NS (∗) and CS (†) (Friedman test with Dunn’s post hoc
test).
This generalised increase in serum cytokines was further
investigated by identifying subjects with serum cytokine
concentrations higher than the 50th percentile (i.e., median)
concentrations seen in the NS control group, which are
shown for each cytokine by the dotted lines in the graphs
in Figure 1. By definition, less than 50% of the NS subjects
had concentrations above the NS group median values for all
cytokines. By contrast, Figure 1 shows that the median levels
of several cytokines (shown by the solid bars) are higher than
the NS median in the CS and COPD groups. Indeed, in the
CS group and COPD S1, S2, and S3 groups, several cytokines
had serum concentrations greater than the NS group median
values in at least two-thirds (≥67%) of the subjects: this was
the case for MCP-1 in all four groups (CS and S1–3); for IL-8
in the S1–3; for VEGF in S1 and S2; for IFN-𝛾, IL-6 and TNF𝛼
in S2 and S3; and for IL-17 in S3 only.
Figure 4(a) presents the ratios of the median concentra-
tions of each cytokine in each group relative to the NS control
group. Collectively, these values are significantly higher in
the S2 (†) and S3 (†††) groups compared to the CS group
(Friedman test with Dunn’s post hoc test). Figures 4(b)–
4(d) show plots of these ratios for each cytokine separated
into “Th1/Th2/Treg” cytokines (Figure 4(b)), “chemokines”
(Figure 4(c)) and “inflammatory cytokines and growth fac-
tor” (Figure 4(d)). The symbol for each cytokine is indicated
in the figure; IL-17 (× in Figures 2 and 3) is not shown in
Figures 4(b)–4(d) because the median of the NS group was 0
(Figure 1(c)), so ratios could not be derived.
4. Discussion
Our findings are consistent with those of others who have
shown elevated levels of serum cytokines in COPD, partic-
ularly with regard to IL-6, IL-8, TNF𝛼, and VEGF [11–16, 18,
20]. We found certain individual circulating cytokines (par-
ticularly TNF𝛼 and IL-1𝛽) to be significantly elevated in con-
centration in the serum of some COPD patients (and some
current smokers not diagnosed with COPD), and these may
serve as markers of particularly significant systemic inflam-
mation.However, we also found a broad increase in the serum
concentration of numerous circulating cytokines that was
collectively significant (and of possible biological relevance),
but without a sufficiently great increase in concentration
across all patients being statistically significant for individual
cytokines. Hence, this indicates the value of detecting numer-
ous cytokines rather than just a few. The serum levels of this
collection of cytokines correlated with the severity of COPD
(GOLD stages 1–3), and theymay be further indicators of, and
contributors to, the systemic inflammatory manifestations of
COPD.
The broad, relatively subtle, elevation of multiple circu-
lating cytokines is also consistent with the insidious devel-
opment and chronic nature of COPD. Indeed, this pattern of
moderate, but persistent cytokine elevationmay also occur in
other chronic conditions, including metabolic syndrome and
cardiovascular disease, which are also associated with COPD
[26, 27].
Amore detailed analysis of the trends in cytokine expres-
sion represented in Figures 4(b)–4(d) raises a number of
interesting points. Firstly, some cytokines appear to be ele-
vated as a consequence of smoking per se, particularly, IFN-
𝛾, TGF𝛽, IL-8, and MCP-1. Secondly, most of the cytokines
studied are elevated in COPD patients, particularly in S2 and
S3; this applies to all except IL-4, eotaxin-1, and eotaxin-2 (i.e.,
Th2-profile cytokines). Thirdly, only VEGF is elevated in all
three stages of COPD (S1–3) relative to CS. This is consistent
with other reports of the particular importance of VEGF in
COPD and the fact that hypoxia is a known inducer of VEGF
[28–30]. Proinflammatory cytokines, including ones found
to be elevated in the present study, are known inducers of
VEGF expression by alveolar epithelial cells [31]. Finally, IL-
1𝛽 appears to be suppressed in CS and S1. At first site, this
appears surprising given that IL-1𝛽 (together with TNF𝛼)
was the best discriminator of patients with cytokine levels
>95th percentile of the NS group. However, this is because
CS and COPD subjects tend to have either low levels of IL-
1𝛽 or high levels (above 95th percentile of NS), rather than an
even spread (as shown in Figure 1(m)). Indeed, it is interesting
to note that the serum cytokines IL-1𝛽 and IL-4, which were
significantly elevated (above the 95th percentile of the NS
controls) in certain individual subjects, were not generally
raised in theCS orCOPDgroups.Thismight be because these
cytokines are associated with particular disease manifesta-
tions rather than the generalised, systemic, low-grade inflam-
mation associated with COPD. Our study suggests that the
latter phenotype ismore associated with IFN-𝛾, IL-17,MCP-1,
IL-8, VEGF, IL-6, and TNF𝛼 from amongst the cytokines we
measured.
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The findings of the present study can be put into the
context of “systems biology” of disease processes, in which
a combination of technological and analytical advances has
facilitated understanding of the complexity of factors that
contribute to pathogenesis and phenotype of diseases.This, in
turn, has led to the realisation that multiple, interacting fac-
tors can have a significant impact on disease development in
combination, but not individually. Examples in other types of
disease include the subtle, constitutive activation of multiple
proinflammatory signalling pathways in certain autoinflam-
matory disorders [32] and patterns of reactivity of multiple
natural autoantibodies with tumours [33].
5. Conclusions
In conclusion, numerous cytokines are raised in the circula-
tion of COPD patients such that the combined, but not indi-
vidual, elevation of these cytokines is significantly associated
with severity of disease. Furthermore, these cytokines may be
indicators of, and contributors to, the systemic inflammatory
manifestations of COPD and the pattern of multiple serum
cytokines may be more informative of systemic aspects of the
disease than individual cytokines. The coelevation of numer-
ous circulating cytokines in COPD is consistent with the
insidious development, chronic nature, and systemic comor-
bidities of this disease.
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